About: Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.29 (+2.49%)
VRCA NASDAQ Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc share price
VRCA price activity
Last Price
$3.290
Change (24hr)
0.08 USD (2.49%)
Volume
44.87K
Volume (4w avg)
-
Open
$3.35
Day Range
$3.25 - $3.42
Previous Close
$3.21
Last Trade
03 Nov, 9:02 pm GMT+0
Delayed
03 Nov, 9:02 pm GMT+0
VRCA price performance
Delayed
03 Nov, 9:02 pm GMT+0
VRCA details
VRCA Market Signals